The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis
ObjectiveThis study systematically evaluated the efficacy of programmed death 1 (PD-1) inhibitors combined with chemotherapy for advanced esophageal cancer (EC).MethodsPubMed, Embase, Web of Science, Scopus, and Cochrane Library were searched to identify related randomized controlled trials (RCTs).R...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1515263/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846091466070294528 |
|---|---|
| author | Jian-Zhou Tian Li Zhang Fu-Yong Lin Ren-Jiao He Wen-Rong Tian Liu Yan Guo-Xin Huang Jin-Wei Ai Jin-Wei Ai Jin-Wei Ai Bin Pei Bin Pei De-Sheng Li |
| author_facet | Jian-Zhou Tian Li Zhang Fu-Yong Lin Ren-Jiao He Wen-Rong Tian Liu Yan Guo-Xin Huang Jin-Wei Ai Jin-Wei Ai Jin-Wei Ai Bin Pei Bin Pei De-Sheng Li |
| author_sort | Jian-Zhou Tian |
| collection | DOAJ |
| description | ObjectiveThis study systematically evaluated the efficacy of programmed death 1 (PD-1) inhibitors combined with chemotherapy for advanced esophageal cancer (EC).MethodsPubMed, Embase, Web of Science, Scopus, and Cochrane Library were searched to identify related randomized controlled trials (RCTs).ResultsSeven RCTs involving 4,363 participants were included. The results of the direct comparison showed that, compared with chemotherapy alone, PD-1 inhibitors combined with chemotherapy significantly improved overall survival (OS) (HR = 0.69, 95%CI = 0.63–0.74), progression-free survival (PFS) (HR = 0.63, 95%CI = 0.58–0.67), objective response rate (ORR) (RR = 1.41, 95%CI = 1.28–1.57), but were associated with a slight increase in treatment-related adverse events (AEs) (RR = 1.08, 95%CI = 1.03–1.14). The results of the network meta-analysis showed that toripalimab, sintilimab or camrelizumab, and nivolumab combined with chemotherapy were the best in OS, PFS, and ORR, respectively, with camrelizumab showing the lowest incidence of AEs.ConclusionThese results suggest that PD-1 inhibitors combined with chemotherapy provide superior clinical benefits over chemotherapy alone, albeit with a moderate increase in AEs. However, further verification through multi-center, high-quality RCTs with larger sample sizes is needed to confirm these findings.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024627485. |
| format | Article |
| id | doaj-art-d8217fa5ca4049b2bd71878dd7c0061a |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-d8217fa5ca4049b2bd71878dd7c0061a2025-01-10T06:10:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.15152631515263The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysisJian-Zhou Tian0Li Zhang1Fu-Yong Lin2Ren-Jiao He3Wen-Rong Tian4Liu Yan5Guo-Xin Huang6Jin-Wei Ai7Jin-Wei Ai8Jin-Wei Ai9Bin Pei10Bin Pei11De-Sheng Li12Evidence-Based Medicine Center, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaDepartment of Central Sterile Supply, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Plastic Surgery and Regenerative Medicine, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment Three of Orthopedics/Plastic Surgery, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaDepartment of Plastic Surgery and Regenerative Medicine, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment of Plastic Surgery and Regenerative Medicine, Fujian Medical University Union Hospital, Fuzhou, ChinaEvidence-Based Medicine Center, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaEvidence-Based Medicine Center, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaDepartment of Plastic Surgery and Regenerative Medicine, Fujian Medical University Union Hospital, Fuzhou, ChinaDepartment Three of Orthopedics/Plastic Surgery, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaEvidence-Based Medicine Center, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaDepartment Three of Orthopedics/Plastic Surgery, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaDepartment Three of Orthopedics/Plastic Surgery, Xiangyang No.1 People’s Hospital, Hubei University of Medicine, Xiangyang, ChinaObjectiveThis study systematically evaluated the efficacy of programmed death 1 (PD-1) inhibitors combined with chemotherapy for advanced esophageal cancer (EC).MethodsPubMed, Embase, Web of Science, Scopus, and Cochrane Library were searched to identify related randomized controlled trials (RCTs).ResultsSeven RCTs involving 4,363 participants were included. The results of the direct comparison showed that, compared with chemotherapy alone, PD-1 inhibitors combined with chemotherapy significantly improved overall survival (OS) (HR = 0.69, 95%CI = 0.63–0.74), progression-free survival (PFS) (HR = 0.63, 95%CI = 0.58–0.67), objective response rate (ORR) (RR = 1.41, 95%CI = 1.28–1.57), but were associated with a slight increase in treatment-related adverse events (AEs) (RR = 1.08, 95%CI = 1.03–1.14). The results of the network meta-analysis showed that toripalimab, sintilimab or camrelizumab, and nivolumab combined with chemotherapy were the best in OS, PFS, and ORR, respectively, with camrelizumab showing the lowest incidence of AEs.ConclusionThese results suggest that PD-1 inhibitors combined with chemotherapy provide superior clinical benefits over chemotherapy alone, albeit with a moderate increase in AEs. However, further verification through multi-center, high-quality RCTs with larger sample sizes is needed to confirm these findings.Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024627485.https://www.frontiersin.org/articles/10.3389/fmed.2024.1515263/fulladvanced esophageal cancerPD-1 inhibitorschemotherapycombined therapynetwork meta-analysis |
| spellingShingle | Jian-Zhou Tian Li Zhang Fu-Yong Lin Ren-Jiao He Wen-Rong Tian Liu Yan Guo-Xin Huang Jin-Wei Ai Jin-Wei Ai Jin-Wei Ai Bin Pei Bin Pei De-Sheng Li The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis Frontiers in Medicine advanced esophageal cancer PD-1 inhibitors chemotherapy combined therapy network meta-analysis |
| title | The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis |
| title_full | The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis |
| title_fullStr | The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis |
| title_full_unstemmed | The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis |
| title_short | The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis |
| title_sort | efficacy and safety of pd 1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer a network meta analysis |
| topic | advanced esophageal cancer PD-1 inhibitors chemotherapy combined therapy network meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1515263/full |
| work_keys_str_mv | AT jianzhoutian theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT lizhang theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT fuyonglin theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT renjiaohe theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT wenrongtian theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT liuyan theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT guoxinhuang theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT jinweiai theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT jinweiai theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT jinweiai theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT binpei theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT binpei theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT deshengli theefficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT jianzhoutian efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT lizhang efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT fuyonglin efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT renjiaohe efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT wenrongtian efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT liuyan efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT guoxinhuang efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT jinweiai efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT jinweiai efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT jinweiai efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT binpei efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT binpei efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis AT deshengli efficacyandsafetyofpd1inhibitorscombinedwithchemotherapytreatmentforadvancedesophagealcanceranetworkmetaanalysis |